Evotec AG has entered into a non-exclusive license agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology.

Evotec gains access to IP related to CRISPR-Cas9 and will apply the technology to its drug discovery offerings and R&D activities, as well as for the development of research tools in target identification, and to further strengthen its post phenotypical screening target deconvolution platform.

Dr. Mario Polywka, chief operating officer of Evotec, said, “Alongside Evotec’s comprehensive stem cell capabilities, the ability to offer CRISPR-Cas9 research tools emphasises the Company’s continuing approach to establishing cutting-edge technologies for the benefit of our partners and growing R&D pipeline.”